

From: [NLCP](#)
To: [NLCP](#)
Subject: NLCP Notice: 2017 Federal CCF Use
Date: Monday, November 29, 2021 12:58:36 PM

CAUTION: This email originated from outside of the Department of Transportation (DOT). Do not click on links or open attachments unless you recognize the sender and know the content is safe.

ATTENTION: HHS-Certified Laboratories, Applicant Laboratories, and NLCP Inspectors

Subject: 2017 Federal CCF Use

HHS-certified laboratories: Please forward this email to Medical Review Officers (MROs), collection sites for federal workplace drug testing programs.

The Office of Management and Budget (OMB) has granted an extension for using the 2017 Federal Custody and Control Form (CCF) for urine specimens until **August 31, 2023**. With this extension, either the 2020 Federal CCF or the expired 2017 Federal CCF may be used for urine specimens collected for federal workplace drug testing programs and those collected for testing under the Department of Transportation (DOT) regulations. **With this change, the use of the 2017 Federal CCF is now permitted (as of November 23, 2021) without a memorandum for the record (MFR).** The use of the 2017 Federal CCF for specimens collected prior to that date requires an MFR.

The Substance Abuse and Mental Health Services Administration (SAMHSA) requested OMB approval for continued use of the 2017 Federal CCF due to a shortage of raw materials needed for the 2020 Federal CCF, reported to SAMHSA by DOT and HHS-certified laboratories. Short supplies include the carbonless paper used for CCF and the resins and plastics used for the labels directly affixed to the form. Items used for specimen collection kits (e.g., cardboard, shipping materials) are also in short supply. These shortages are attributed to the materials' use for COVID-related activities. Additionally, it was noted there is only one supplier of the carbonless paper and the supplier has indicated they will not be increasing its production.

SAMHSA continues to support efforts to continue workplace drug testing during the COVID-19 pandemic to protect the health and safety of employees, maintain public safety, and sustain US workforce productivity. This change is intended to reduce burden on all drug testing service providers (e.g., collectors, laboratories, Medical Review Officers) and to preserve the supply use by the non-regulated sector, which uses the same materials as the federally regulated sector.

The OMB Notice of Action may be viewed here: [View Information Collection Request \(ICR\) Package \(reginfo.gov\)](#)